Antivascular and antiangiogenic agents, including bortezomib and thalidomide, have cytotoxic effects on MM cells and ECs by inhibiting the secretion of multiple angiogenic factors including VEGF, HGF and FGF-2 [24, 25]. This evidence concerns the gene HGF and Miyoshi myopathy.